...
机译:P2.13-21可以通过AXL在MET扩增的初级抗性EGFR-突变体NSCLCX中通过AXL来避免成瘾。
Department of Medical Oncology National Cancer Center Singapore;
Department of Medical Oncology National Cancer Center Singapore;
Genome Institute of Singapore;
Genome Institute of Singapore;
Genome Institute of Singapore;
Department of Medical Oncology National Cancer Center Singapore;
Genome Institute of Singapore;
Department of Medical Oncology National Cancer Center Singapore;
Genome Institute of Singapore;
Genome Institute of Singapore;
Genome Institute of Singapore;
Surgical Oncology National Cancer Centre Singapore;
Surgical Oncology National Cancer Centre Singapore;
Surgical Oncology National Cancer Centre Singapore;
Surgical Oncology National Cancer Centre Singapore;
Department of Medical Oncology National Cancer Center Singapore;
Department of Medical Oncology National Cancer Center Singapore;
Department of Medical Oncology National Cancer Center Singapore;
Department of Medical Oncology National Cancer Center Singapore;
Department of Medical Oncology National Cancer Center Singapore;
Genome Institute of Singapore;
Genome Institute of Singapore;
Surgical Oncology National Cancer Centre Singapore;
Department of Medical Oncology National Cancer Center Singapore;
机译:P2.13-21可以通过AXL在MET扩增的初级抗性EGFR-突变体NSCLCX中通过AXL来避免成瘾。
机译:Met-TKI / EGFR-TKI联合暴露在Met扩增的EGFR-TKI耐药肺腺癌中具有激活的EGFR突变的获得性耐药机制
机译:OA 09.06 A Savolitinib Plus Gefitinib的A相IB试验为EGFR-突变体MET扩增先进的NSCLC患者
机译:溶胶-凝胶二氧化硅控释薄膜抑制耐甲氧西林金黄色葡萄球菌
机译:评估合理设计的拟肽抑制乳腺癌和肺部恶性肿瘤中EGFRs蛋白相互作用的评估。
机译:阿法替尼和西妥昔单抗对激酶抑制剂耐药的EGFR突变型肺癌的双重抑制无论是否有T790M突变。
机译:Capmatinib Plus Gefitinib在EGFR-突变体MET扩增的肿瘤中有效